Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) is trading at $14.35, about ₹1,377 at today's USD/INR rate, as of 25 Sep 2026, 3:14 PM ET, down 2.87% today. Indian residents can buy Ultragenyx Pharmaceutical from India on Paasa under the RBI's Liberalised Remittance Scheme.
Quote
Today's low
$14.15
Today's high
$14.94
52 week low
$12.73
52 week high
$39.89
RARE opened at $14.82, closed previously at $14.77, and has traded between $12.73 and $39.89 over the past 52 weeks.
About
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical firm dedicated to discovering, developing, and commercializing innovative treatments for rare and ultra-rare genetic conditions. Its operations span North America, Europe, and other international markets. The company's portfolio of marketed biologic products addresses several serious diseases. This includes Crysvita (burosumab), an antibody that targets fibroblast growth factor 23, used to treat X-linked hypophosphatemia and tumor-induced osteomalacia. Mepsevii offers enzyme replacement therapy for both pediatric and adult patients suffering from Mucopolysaccharidosis VII. Dojolvi is available for individuals with long-chain fatty acid oxidation disorders, while Evkeeza (evinacumab) provides a treatment option for homozygous familial hypercholesterolemia. Ultragenyx also boasts a robust pipeline of investigational therapies. Notable candidates include DTX401, an adeno-associated virus 8 (AAV8) gene therapy for glycogen storage disease type Ia, and DTX301, another AAV8 gene therapy aimed at ornithine transcarbamylase deficiency. Other promising developments feature UX143, a human monoclonal antibody for osteogenesis imperfecta; GTX-102, an antisense oligonucleotide designed for Angelman syndrome; UX701, targeting Wilson disease; and UX053, in development for glycogen storage disease type III. To advance its research and development efforts, Ultragenyx Pharmaceutical Inc. maintains strategic collaboration and licensing agreements with numerous partners, such as Kyowa Kirin Co., Ltd., Saint Louis University, REGENXBIO Inc., Bayer Healthcare LLC, GeneTx, Mereo, University of Pennsylvania, Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc., and Daiichi Sankyo Co., Ltd. The company was founded in 2010 and operates from its headquarters in Novato, California.
Key statistics
Avg. volume
3.26M
Market cap
$1.41B
P/E Ratio
-2.46
Price-to-sales ratio
1.97
Enterprise value
$2.49B
Free cash flow yield
-34.64%
Debt-to-equity ratio
-4.13
Return on equity
392.35%
ROIC
-53.48%
Beta
0.32
Dividend yield
0.00%
Last dividend
$0.00
Financial overview
Revenue
$673.00M
Earnings per share
-$5.83
Free cash flow
-$472.00M
Net profit margin
-81.79%
Gross margin
83.12%
EBITDA
-$474.00M
Revenue growth
20.13%
Similar securities
This is not an investment recommendation
How to buy Ultragenyx Pharmaceutical from India
Indian residents can buy Ultragenyx Pharmaceutical shares through Paasa in four steps. Funds leave India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name with Interactive Brokers.
Open a Paasa account
Complete digital KYC with your PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Add funds under LRS
Transfer INR from your Indian bank account. Your bank reports the remittance under the RBI's Liberalised Remittance Scheme and converts it to US dollars.
Search for Ultragenyx Pharmaceutical and place an order
Find Ultragenyx Pharmaceutical by name or by its ticker, RARE, and choose an order type. You can buy by amount or by quantity — fractional shares mean there is no minimum trade size. Ultragenyx Pharmaceutical trades 7:00 pm – 1:30 am IST; orders can only execute during that window.
Track holdings and download tax reports
Follow your Ultragenyx Pharmaceutical position in USD and INR. Ultragenyx Pharmaceutical pays no dividend today, so your filing is the capital-gains statement plus the Schedule FA holding line.
Read the full guide: how to invest in Ultragenyx Pharmaceutical from India
Trading and taxes when buying Ultragenyx Pharmaceutical from India
Trading and limits
- Trading hours
- 9:30 am – 4:00 pm ET
- LRS limit
- $250,000Per financial year, under the RBI's Liberalised Remittance Scheme.
Tax for Indian residents
- TCS on remittance
- 20%Collected by your bank on LRS remittances above ₹10 lakh in a financial year. The TCS is adjustable against your income-tax liability.Adjusting TCS against your tax
- Capital gains in India
- 12.5% or slab rateGains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate.Capital gains explained
- Dividends
- NoneUltragenyx Pharmaceutical does not currently pay a dividend. If it starts, dividends are taxed at your slab rate in India.Dividend tax explained
- US estate tax
- May applyUS-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons.US estate tax calculator
Custody. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
FAQs
Can Indian residents buy Ultragenyx Pharmaceutical stock?
Yes. Ultragenyx Pharmaceutical (RARE) has been listed on NASDAQ since 2014, in the Biotechnology industry, and Indian residents can buy it through Paasa. You fund the account from your Indian bank under the RBI's Liberalised Remittance Scheme and the money is converted to US dollars. Shares are held in your own name at Interactive Brokers LLC and are SIPC-insured up to $500,000 in total, including $250,000 for cash.
How much does one Ultragenyx Pharmaceutical share cost in rupees?
One Ultragenyx Pharmaceutical share is $14.35 — about ₹1,377 at a USD/INR rate of 96.02 on 24 Sep 2026. Both the Ultragenyx Pharmaceutical price and the rupee rate move during the day, so the rupee cost changes with them.
What are the LRS and TCS rules for buying Ultragenyx Pharmaceutical from India?
Remit up to $250,000 per financial year under the RBI's Liberalised Remittance Scheme (LRS). Banks collect 20% tax at source on LRS remittances above ₹10 lakh in a financial year; the TCS is adjustable against your income-tax liability. FX and the LRS declaration are handled by your bank when you fund your account.
Can I buy whole shares of Ultragenyx Pharmaceutical?
Yes. One Ultragenyx Pharmaceutical share is $14.35, and you can buy as many whole shares as you like. You can also buy by amount rather than by quantity: there is no minimum trade size, and Paasa supports fractional investing in Ultragenyx Pharmaceutical.
How are gains on Ultragenyx Pharmaceutical shares taxed in India?
The US does not levy capital gains tax on shares for Indian residents, so the tax is an India-side one. Gains on shares held for more than 24 months are long-term and taxed at 12.5%. Gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. The gain is computed in rupees using the USD/INR rate on the purchase and the sale date, so the rupee move counts alongside the Ultragenyx Pharmaceutical price. Paasa issues a capital-gains statement for your return.
Does Ultragenyx Pharmaceutical pay a dividend?
No. Ultragenyx Pharmaceutical does not currently pay a dividend, so holding it produces no dividend income to declare in India. If it starts paying one, the Indian treatment is the usual one — dividends are taxed at your slab rate in India — and Paasa's dividend report would show the gross amount and any tax withheld.
When can I trade Ultragenyx Pharmaceutical from India?
NASDAQ trades 7:00 pm – 1:30 am IST in Indian time, so the close lands after midnight. The window shifts to 8:00 pm – 2:30 am IST when the US is on standard time. Orders can only execute during that window.
Is there estate or inheritance tax on Ultragenyx Pharmaceutical shares held from India?
US-situs assets such as US-listed shares can be exposed to US estate tax for non-US persons. It applies to your overall holdings in that jurisdiction rather than to any one position. Paasa's US estate tax calculator shows the exposure for a given portfolio value.
Do I have to declare Ultragenyx Pharmaceutical shares in my Indian tax return?
Yes. Foreign shares held on 31 March must be reported in Schedule FA of your Indian income-tax return. Paasa gives you a Schedule FA-ready statement listing your Ultragenyx Pharmaceutical holding, its cost and its closing value.
How do I sell Ultragenyx Pharmaceutical and bring the money back to India?
You sell during market hours (7:00 pm – 1:30 am IST) and the proceeds settle in USD in your Paasa account. From there you can hold the balance, reinvest, or repatriate. Funds can be withdrawn in any currency to any bank account in your own name. Whether the sale is short- or long-term is decided by the 24-month holding period.